search
Back to results

Behavioural Activation for Bipolar Depression: A Case Series (BA-BD)

Primary Purpose

Bipolar Depression

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Behavioural Activation (BA)
Sponsored by
University of Exeter
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bipolar Depression focused on measuring Behavioural Activation, Bipolar Disorder, Bipolar Depression, Multiple Baseline, Case Series

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • scoring in the clinical range on a self-report measure of depression severity (the PHQ-9)
  • meeting diagnostic criteria for depression based on a Structured Clinical Interview for Diagnosis (SCID-5)
  • meeting diagnostic criteria for Bipolar I or II Disorder (SCID-5)
  • participants will require working knowledge of written and spoken English, sufficient to be able to make use of therapy and to be able complete research assessments without the need of a translator.

Exclusion Criteria:

  • current/past learning disability, organic brain change, substance dependence (drugs and alcohol) that would compromise ability to use therapy
  • current marked risk to self (i.e. self-harm or suicide) that we deem could not be appropriately managed in the AccEPT clinic at the Mood Disorders Centre
  • currently lacking capacity to give informed consent
  • currently receiving other psychosocial therapy for depression or bipolar disorder
  • presence of another area of difficulty that the therapist and client believe should be the primary focus of intervention (for example, Post-Traumatic Stress Disorder, psychosis).

Sites / Locations

  • University of Exeter

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Other

Other

Other

Other

Other

Other

Arm Label

3 week wait

4 week wait

5 week wait

6 week wait

7 week wait

8 week wait

Arm Description

Participant waits for 3 weeks after their baseline assessment before commencing therapy.

Participant waits for 4 weeks after their baseline assessment before commencing therapy.

Participant waits for 5 weeks after their baseline assessment before commencing therapy.

Participant waits for 6 weeks after their baseline assessment before commencing therapy.

Participant waits for 7 weeks after their baseline assessment before commencing therapy.

Participant waits for 8 weeks after their baseline assessment before commencing therapy.

Outcomes

Primary Outcome Measures

Minimally clinically significant improvement in depression symptoms for a majority of participants (>60%)
Participants' weekly completion of the Patient Health Questionnaire-9 (PHQ-9)
No significant adverse reaction for participants
Participant reports of adverse events elicited by researchers and therapists.
Qualitative feedback from participants
Written and verbal feedback of participants
Qualitative feedback from therapists
Feedback given in qualitative interviews with therapists
Therapy uptake rate
Number of participants randomised who attend at least 1 treatment session
Therapy completion rate
Proportion of participants that attend at least 8 treatment sessions

Secondary Outcome Measures

Altman Self-Rating Mania Scale (ASRM)
5 item self-report measure of hypomania symptoms over the past week
Work and Social Adjustment Scale (WSAS)
5 item self-report scale of functional impairment attributable to an identified problem
Structured Clinical Interview for Depression (SCID)
Standardised interview to establish whether the participant meets research diagnostic criteria for lifetime Bipolar I or II Disorder, current depressive episode, and to establish whether they are experiencing current substance dependence
Hamilton Depression Scale (HAM-D)
17 item observer-rated scale measuring symptoms of depression over the past week
Brief Quality of Life in Bipolar Disorder (Brief QoLBD)
12 item self-report measure of disorder-specific quality of life
Bech-Rafaelsen Mania Scale
11 item observer-rated scale measuring the severity of manic states
Beck Depression Inventory (BDI)
21 item self-report measure of depressive symptoms and attitudes
General Anxiety Disorder Assessment - 7 (GAD7)
7 item self-report measure of anxiety symptoms
Behavioral Activation for Depression Scale (BADS)
25 item self-report measure of changes in activation and avoidance over the past week
Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS)
7-item self-report measure of wellbeing
Snaith-Hamilton Pleasure Scale (SHAPS)
14 item self-report measure of level of anhedonia
Positive and Negative Urgency Subscales of the UPPS-P Impulsive Behavior Scale
14 and 12 items respectively, these self-report scales measure tendency to respond impulsively to positive or negative feelings
Questions about Suffering, Struggling and Engagement in Valued Activities
3 item self-report measure of core hypothesised process of change in behavioural activation, namely reduction in avoidance behaviours and increase in rewarding behaviours

Full Information

First Posted
July 26, 2018
Last Updated
April 27, 2021
Sponsor
University of Exeter
Collaborators
Devon Partnership NHS Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT03658824
Brief Title
Behavioural Activation for Bipolar Depression: A Case Series
Acronym
BA-BD
Official Title
Behavioural Activation for Bipolar Depression (BA-BD): A Case Series Evaluation
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
September 1, 2018 (Actual)
Primary Completion Date
March 31, 2021 (Actual)
Study Completion Date
March 31, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Exeter
Collaborators
Devon Partnership NHS Trust

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Bipolar Disorders affect around 2% of the population. Most people with Bipolar experience depression; these periods can cause difficulties with relationships, work and daily life. Psychological therapies for "unipolar" depression (for people who experience depression but never mania or hypomania) are widely available, but there is little research in to how effective these therapies are for people with Bipolar. Knowing this could give greater choice to people with Bipolar in terms of the therapy they have, and how easy it is to get within the NHS. One such therapy is called Behavioural Activation (BA). BA is an established therapy for people with unipolar depression. It helps people to re-establish healthier patterns of activity, but so far there is very little research into offering BA to people with BD. The current research involves a small number of people with Bipolar Depression receiving BA to see if it seems sensible and worthwhile to them, and to help us to make any necessary improvements to the therapy. The study is taking place in Devon and is sponsored by the University of Exeter. 12 people that are currently experiencing Bipolar Depression who choose to take part will receive up to 20 individual therapy sessions of BA that has been adapted for Bipolar Depression (BA-BD), and will complete regular questionnaires and interviews. The results of this study will not give the final answer on how effective BA is for people with bipolar depression, but will help to plan for a larger study that can answer this question.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Depression
Keywords
Behavioural Activation, Bipolar Disorder, Bipolar Depression, Multiple Baseline, Case Series

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a case series using a multiple baseline design whereby participants are randomly allocated to one of 6 durations of wait at baseline before commencing treatment.
Masking
None (Open Label)
Masking Description
It is not possible to blind the assessor to phase or baseline duration of participants in the case-series, as the length of time between assessments will reveal this. Nevertheless, the assessor and clients will be asked not to disclose which therapist is treating them. Use of self-report measures as the primary outcome measure is intended to minimise potential biases on the side of the researcher.
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
3 week wait
Arm Type
Other
Arm Description
Participant waits for 3 weeks after their baseline assessment before commencing therapy.
Arm Title
4 week wait
Arm Type
Other
Arm Description
Participant waits for 4 weeks after their baseline assessment before commencing therapy.
Arm Title
5 week wait
Arm Type
Other
Arm Description
Participant waits for 5 weeks after their baseline assessment before commencing therapy.
Arm Title
6 week wait
Arm Type
Other
Arm Description
Participant waits for 6 weeks after their baseline assessment before commencing therapy.
Arm Title
7 week wait
Arm Type
Other
Arm Description
Participant waits for 7 weeks after their baseline assessment before commencing therapy.
Arm Title
8 week wait
Arm Type
Other
Arm Description
Participant waits for 8 weeks after their baseline assessment before commencing therapy.
Intervention Type
Other
Intervention Name(s)
Behavioural Activation (BA)
Intervention Description
BA is based on the assumption that depression may be precipitated and is maintained by a reduction in "healthy", adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term. The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions.
Primary Outcome Measure Information:
Title
Minimally clinically significant improvement in depression symptoms for a majority of participants (>60%)
Description
Participants' weekly completion of the Patient Health Questionnaire-9 (PHQ-9)
Time Frame
through study completion, an average of 7 months
Title
No significant adverse reaction for participants
Description
Participant reports of adverse events elicited by researchers and therapists.
Time Frame
through study completion, an average of 7 months
Title
Qualitative feedback from participants
Description
Written and verbal feedback of participants
Time Frame
through study completion, an average of 7 months
Title
Qualitative feedback from therapists
Description
Feedback given in qualitative interviews with therapists
Time Frame
through study completion, an average of 7 months
Title
Therapy uptake rate
Description
Number of participants randomised who attend at least 1 treatment session
Time Frame
through study completion, an average of 7 months
Title
Therapy completion rate
Description
Proportion of participants that attend at least 8 treatment sessions
Time Frame
through study completion, an average of 7 months
Secondary Outcome Measure Information:
Title
Altman Self-Rating Mania Scale (ASRM)
Description
5 item self-report measure of hypomania symptoms over the past week
Time Frame
1 week
Title
Work and Social Adjustment Scale (WSAS)
Description
5 item self-report scale of functional impairment attributable to an identified problem
Time Frame
24 hours
Title
Structured Clinical Interview for Depression (SCID)
Description
Standardised interview to establish whether the participant meets research diagnostic criteria for lifetime Bipolar I or II Disorder, current depressive episode, and to establish whether they are experiencing current substance dependence
Time Frame
Six months
Title
Hamilton Depression Scale (HAM-D)
Description
17 item observer-rated scale measuring symptoms of depression over the past week
Time Frame
1 week
Title
Brief Quality of Life in Bipolar Disorder (Brief QoLBD)
Description
12 item self-report measure of disorder-specific quality of life
Time Frame
1 week
Title
Bech-Rafaelsen Mania Scale
Description
11 item observer-rated scale measuring the severity of manic states
Time Frame
1 week
Title
Beck Depression Inventory (BDI)
Description
21 item self-report measure of depressive symptoms and attitudes
Time Frame
1 week
Title
General Anxiety Disorder Assessment - 7 (GAD7)
Description
7 item self-report measure of anxiety symptoms
Time Frame
2 weeks
Title
Behavioral Activation for Depression Scale (BADS)
Description
25 item self-report measure of changes in activation and avoidance over the past week
Time Frame
1 week
Title
Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS)
Description
7-item self-report measure of wellbeing
Time Frame
2 weeks
Title
Snaith-Hamilton Pleasure Scale (SHAPS)
Description
14 item self-report measure of level of anhedonia
Time Frame
1 week
Title
Positive and Negative Urgency Subscales of the UPPS-P Impulsive Behavior Scale
Description
14 and 12 items respectively, these self-report scales measure tendency to respond impulsively to positive or negative feelings
Time Frame
6 months
Title
Questions about Suffering, Struggling and Engagement in Valued Activities
Description
3 item self-report measure of core hypothesised process of change in behavioural activation, namely reduction in avoidance behaviours and increase in rewarding behaviours
Time Frame
24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: scoring in the clinical range on a self-report measure of depression severity (the PHQ-9) meeting diagnostic criteria for depression based on a Structured Clinical Interview for Diagnosis (SCID-5) meeting diagnostic criteria for Bipolar I or II Disorder (SCID-5) participants will require working knowledge of written and spoken English, sufficient to be able to make use of therapy and to be able complete research assessments without the need of a translator. Exclusion Criteria: current/past learning disability, organic brain change, substance dependence (drugs and alcohol) that would compromise ability to use therapy current marked risk to self (i.e. self-harm or suicide) that we deem could not be appropriately managed in the AccEPT clinic at the Mood Disorders Centre currently lacking capacity to give informed consent currently receiving other psychosocial therapy for depression or bipolar disorder presence of another area of difficulty that the therapist and client believe should be the primary focus of intervention (for example, Post-Traumatic Stress Disorder, psychosis).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kim A Wright, PhD
Organizational Affiliation
University of Exeter
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Exeter
City
Exeter
ZIP/Postal Code
EX4 4QG
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All data that underlie results in a publication.
IPD Sharing Time Frame
Access will be possible from date of publication.
IPD Sharing Access Criteria
The research database will be registered with the University of Exeter public access database. The dataset will be anonymous and will be registered with a metadata only record, allowing the research team to control access to the dataset, restricting it to appropriately qualified third parties.

Learn more about this trial

Behavioural Activation for Bipolar Depression: A Case Series

We'll reach out to this number within 24 hrs